Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed through laboratory testing with locally advanced (Stage IIIB or IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) — either squamous or non-squamous type — where surgery to fully remove the cancer and curative radiation/chemotherapy combined treatment are not suitable options
- People whose cancer has been tested for a marker called PD-L1, with results available
- People in Part B of the trial only: those whose PD-L1 test result shows a score of 1% or higher
- People whose cancer has at least one measurable area that can be tracked using standard imaging guidelines
- People who are in relatively good general health, able to carry out normal daily activities with little or no limitation (scored 0 or 1 on a standard health scale used in cancer trials)
- People whose liver, kidneys, and other organs are functioning well enough to meet the trial's health requirements
Who may not be able to join:
- People whose cancer has certain known genetic mutations or changes — specifically in genes called EGFR, ALK, ROS1, NTRK, BRAF, or MET
- People who have had another cancer diagnosed within the past 3 years, or who still show signs of a previously diagnosed cancer
- People with known active cancer spread to the brain, brainstem, spinal cord, or the membranes surrounding the brain or spinal cord
- People with a condition called leptomeningeal disease, where cancer has spread to the fluid and membranes surrounding the brain and spinal cord
- People who have an active autoimmune disease (where the immune system attacks the body) that has required ongoing medical treatment within the past 2 years
- People who have previously received systemic (whole-body) treatment for locally advanced, unresectable, or metastatic NSCLC
- People who have previously received immunotherapy (with the exception of certain early-stage preventive immunotherapy treatments), a specific type of antibody-drug therapy containing a payload called MMAE, systemic anti-blood vessel growth therapy, or radiation treatment to the lung within 6 months before joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Phone: 1-800-718-1021
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs); Phase I: Number of participants with dose limiting toxicity (DLT); Phase 2: Confirmed Objective Response Rate (ORR) per RECIST v1.1 by investigator
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.